T1 hyperintensity of bladder urine at prostate MRI: frequency and comparison with urinalysis findings
Received 10 April 2010; accepted 1 May 2010. published online 14 July 2010. Corrected Proof
Abstract
Objective
The purpose of this study was to assess the possible clinical significance of bladder urine T1 hyperintensity based upon comparison with urinalysis findings, using a cohort of patients who underwent prostate MRI and urinalysis at a similar point in time during preoperative work-up.
Methods
We identified 56 patients who underwent prostatectomy at our institution who obtained prostate MRI and urinalysis within 1 day of each other preoperatively. A control group of 160 consecutive adult men who underwent pelvic MRI during the same time period for other indications was also identified. Two radiologists independently and in consensus reviewed the T1-weighted images to assess the frequency of bladder urine T1 hyperintensity in both groups. The urinalyses in the 56 men undergoing prostatectomy were reviewed, with the results compared between patients with and without bladder urine T1 hyperintensity.
Results
Four (7.1%) of 56 men with prostate cancer exhibited T1 hyperintense bladder urine, compared with six (3.8%) of 160 patients exhibiting this finding in the control group (P=.288). Of the four prostate cancer patients with this finding, all exhibited a normal urinalysis. An abnormal urinalysis was identified for four of the prostate cancer patients, all of whom exhibited normal urine T1 signal intensity.
Conclusion
Bladder urine T1 hyperintensity may be seen occasionally in patients with prostate cancer but is not associated with abnormal urinalysis and therefore should not be regarded as a sign of acute urinary pathology.
aDepartment of Radiology, NYU Langone Medical Center, New York, NY 10016, USA
bDepartment of Urology, NYU Langone Medical Center, New York, NY 10016, USA
Corresponding author. Department of Radiology, NYU Langone Medical Center, 550 First Avenue, New York, NY 10016, USA. Tel.: +1 212 263 0232; fax: +1 212 263 6634.
ABSTRACT